Gene therapy combined with IMRT reduces rate of positive prostate biopsy after treatment for intermediate-risk prostate cancer patients

Combining oncolytic adenovirus-mediated cytotoxic gene therapy (OAMCGT) with intensity modulated radiation therapy (IMRT) reduces the risk of having a positive prostate biopsy two years after treatment in intermediate-risk prostate cancer without affecting patients' quality of life, research has determined.